COMPANY
Gateway Bio, Inc.
Funding and NIH signals
- NIH award NIH awarded $735K (SBIR Phase II 5R44TR003255-04, continuation, notice Jul 20, 2026). NIH RePORTER 5R44TR003255-04 (Jul 20, 2026)
Evidence (1 event)
- Jul 20, 2026 · NIH RePORTER 5R44TR003255-04
Organization: GATEWAY BIO, INC.; City/State: DURHAM, NC; Project number: 5R44TR003255-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 735254; Administering IC: National Center for Advancing Translational Sciences; Project title: Scale-up and Toxicity Studies of POEGMA-Uricase; Organization type: Domestic For-Profits
- Jul 20, 2026 · NIH RePORTER 5R44TR003255-04